<DOC>
	<DOCNO>NCT00444626</DOCNO>
	<brief_summary>The purpose research study evaluate safety effectiveness injection DGE Injectable Gel ( hyaluronic acid lidocaine manufacture Genzyme Biosurgery ) compare injection Restylane ( Food Drug Administration ( FDA ) approve dermal filler ) patient undergo cutaneous correction nasolabial fold ( NLFs ) .</brief_summary>
	<brief_title>A Study Compare Safety Effectiveness Non-FDA Approved Device Dermal Gel Extra ( DGE ) FDA Approved Device Correction Nasolabial Folds ( NLFs )</brief_title>
	<detailed_description>This study include Initial Repeat Treatment period . The Initial Treatment period subject evaluator-blinded , randomized split face study subject receive DGE one nasolabial fold Restylane nasolabial fold . Both safety efficacy evaluate . In Repeat Treatment Period , participant receive DGE NLFs . Safety evaluate .</detailed_description>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Prilocaine</mesh_term>
	<mesh_term>EMLA</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Inclusion Criteria ( abbreviated list ) : Bilateral nasolabial fold ( NLF ) severity score 3 4 6 point scale . Exclusion Criteria ( abbreviated list ) : Pregnant/lactating woman . Subjects allergy lidocaine , prilocaine amidetype anesthetic . Had chemical peel NLF area within 4 week prior study entry . In addition , subject restrict undergoing chemical peel NLF area duration study . Had treatment Botox® injection upper 1/3 face within 2 week prior entry study , low 2/3 face within 24 week prior entry . In addition , subject restrict receive Botox injection face duration study . Received prior therapy face and/or neck ( e.g. , dermabrasion , facelift , Thermage® , laser resurfacing , contour thread , nonablative laser treatment ) within 24 week prior study entry . In addition , subject restrict undergoing therapy duration study . Had previous tissue augmentation NLF area within 24 week prior study entry . In addition , subject restrict undergoing tissue augmentation NLF area duration study . Had previous treatment NLF area permanent implant ( e.g. , silicone , Softform® ) longlasting filler ( e.g. , RadiesseTM , Sculptra® , ArteFill® [ Artecoll ] , BioAlcamidTM ) . In addition , subject restrict undergoing treatment permanent implant longlasting filler NLF area duration study . Had evidence scarrelated disease delayed healing activity within one year prior study enrollment . ( Note : subject scar eligible study enrollment , although scar intend treatment site treat . ) Had history keloid formation . Had history hypo hyperpigmentation skin . Had infection , unhealed wound , active inflammatory process ( e.g. , skin eruption cyst , pimple , rash , hive ) injection site ( ) . Immunocompromised/immunosuppressed ( e.g. , HIVpositive , transplant recipient , presently receive chemotherapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>nasolabial fold</keyword>
	<keyword>facial wrinkle</keyword>
</DOC>